(MENAFN- EIN Presswire)
Pulmonary Sarcoidosis Pipeline
LAS VEGAS, NV, UNITED STATES, January 22, 2025 /EINPresswire / -- DelveInsight's,“Pulmonary Sarcoidosis Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Pulmonary Sarcoidosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Sarcoidosis Pipeline Outlook
Key Takeaways from the Pulmonary Sarcoidosis Pipeline Report
.In January 2025:- Bristol-Myers Squibb- The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
.DelveInsight's Pulmonary Sarcoidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Pulmonary Sarcoidosis treatment.
.The leading Pulmonary Sarcoidosis Companies such as Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
.Promising Pulmonary Sarcoidosis Therapies such as BMS-986278, Inhaled Treprostinil, Namilumab, and others
Stay ahead with the most recent pipeline outlook for Pulmonary Sarcoidosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Sarcoidosis Treatment Drugs
Pulmonary Sarcoidosis Emerging Drugs
.CMK 389: Novartis
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.
.ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
Explore groundbreaking therapies and clinical trials in the Pulmonary Sarcoidosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Sarcoidosis Drugs
Pulmonary Sarcoidosis Companies
Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
.Infusion
.Intradermal
.Intramuscular
.Intranasal
.Intravaginal
.Oral
.Parenteral
.Subcutaneous
.Topical
.Molecule Type
Pulmonary Sarcoidosis Products have been categorized under various Molecule types such as
.Vaccines
.Monoclonal Antibody
.Peptides
.Polymer
.Small molecule
.Product Type
Unveil the future of Pulmonary Sarcoidosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Sarcoidosis Market Drivers and Barriers-
Scope of the Pulmonary Sarcoidosis Pipeline Report
.Coverage- Global
.Pulmonary Sarcoidosis Companies- Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
.Pulmonary Sarcoidosis Therapies- BMS-986278, Inhaled Treprostinil, Namilumab, and others.
.Pulmonary Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
.Pulmonary Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pulmonary Sarcoidosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Sarcoidosis Companies, Key Products and Unmet Needs-
Table of Introduction
2 Sarcoidosis: Sarcoidosis– DelveInsight's Analytical Commercial Sarcoidosis Collaboration Stage Products (Phase Name: Company profiles in the detailed Stage Products (Phase profiles in the detailed Stage Products (Phase aTyr profiles in the detailed Stage Products (Phase AI profiles in the detailed Sarcoidosis Key Sarcoidosis Key Sarcoidosis- Unmet Sarcoidosis- Market Drivers and Sarcoidosis- Future Perspectives and Sarcoidosis Analyst Sarcoidosis Key
List of Top Selling Market Research Reports in 2025
Varicose Vein Treatment Devices Market -
Vascular Access Devices Market -
Indwelling Catheters Market -
Healthcare Competitive Benchmarking -
Lymphoedema Market -
Pacemakers Market -
Myeloproliferative Neoplasms Market -
Surgical Mask & Respirator Market -
Nk Cell Therapy Market -
Novel Drug Delivery Devices Market -
Testicular Neoplasm Market -
Phototherapies For Psoriasis Market -
Skin Neoplasm Market -
Microscopy Device Market -
Bone Growth Stimulator Market -
Urea Cycle Disorders Market -
Antibody Drug Conjugate Market -
Total Knee Arthroplasty Market -
Cardiac Implantable Electronic Devices Market -
Dyspepsia Market -
Lactose Intolerance Market -
Medical Marijuana Market -
Asperger Syndrome Market -
Catheter Stabilization Devices Market -
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yash Bhardwaj
DelveInsight
+91 9650213330
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN22012025003118003196ID1109116778
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.